reports
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Bio...
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 taking place from February 11 – 12, 2026 in New York, NY. Fireside Chat Details:Date: Wednesday, February 11, 2026 Time: 11:30 AM ET A live webcast will be available on the...
QUAINT OAK BANCORP, INC. ANNOUNCES FOURTH QUARTER AND YEAR END EARNING...
QUAINT OAK BANCORP, INC. ANNOUNCES FOURTH QUARTER AND YEAR END EARNINGS Southampton, PA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Quaint Oak Bancorp, Inc. (the “Company”) (OTCQB: QNTO), the holding company for Quaint Oak Bank (the “Bank”), announced today net income for the quarter ended December 31, 2025 of $174,000, or $0.07 per basic and diluted share, compared to net income of $1.6 million, or $0.60 per basic and diluted share, for the same period in 2024. Net income for the year ended December 31, 2025 was $322,000, or $0.12 per basic and diluted share, compared to net income of $2.8 millio...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PKG PACKAGING CORPORATION OF AMERICA
SCCO SOUTHERN COPPER CORPORATION
PAA PLAINS ALL AMERICAN PIPELINE L.P.
LXU LSB INDUSTRIES INC.
LNTH LANTHEUS HOLDINGS INC
KMB KIMBERLY-CLARK CORPORATION
JYNT JOINT CORP
HUBB HUBBELL INCORPORATED CLASS B
HRL HORMEL FOODS CORPORATION
GPRK GEOPARK
DAN DANA INCORPORATED
CVS CVS HEALTH CORPORATION
BLL BALL CORPORATION
ASH ASHLAND GLOBAL HOLDINGS INC.
ACD ADECOAGRO S.A.
ADM ARCHER-DANIELS-MIDLAND COMPANY
NYT NEW YORK TIMES COMPANY CLASS A
ATRO ASTRONICS CORPORATION
DRI DARDEN RESTAURANTS INC.
SXC SUNCOKE ENERGY INC.
CDZI CADIZ INC.
TEC TECHNIPFMC PLC
RNGR RANGER ENERGY SERVICES
CSTL CASTLE BIOSCIENCES
APA APA CORPORATION
AKLCP ONTO INNOVATION INC.
PR KOLTSOVO AIRPORT
BG PERMIAN RESOURCES CORPORATION
PRMB BUNGE LIMITED
USAU PRIMO BRANDS CORP
UAN US GOLD CORP
DFTX ARCADIAN PARTNERS LP PFD
VXX DEFINIUM THERAPEUTICS INC.
IPATH SERIES B S&P 500 VIX SHORT-TERM FUTURES ETN
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5...
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WATERTOWN, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the gran...
Quaint Oak Bancorp, Inc. Declares Quarterly Cash Dividend
Quaint Oak Bancorp, Inc. Declares Quarterly Cash Dividend SOUTHAMPTON, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Quaint Oak Bancorp, Inc. (OTCQB: QNTO) (the "Company"), the holding company for Quaint Oak Bank, announced today that its Board of Directors declared a quarterly cash dividend of $0.04 per share on the common stock of the Company on January 14, 2026. The dividend is payable on February 9, 2026, to the shareholders of record at the close of business on January 26, 2026. Quaint Oak Bancorp, Inc., a Financial Services Company, is the parent company for the Quaint Oak Family of Compa...
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide a...
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026 Internal Discovery Strategy Progressing Efforts Focused on Inflammation, Neuro-inflammation and Neuro-degenerative Diseases With Novel Targets in Clinically Validated Pathways Cash Runway to End of 2028 ...
Sensient Technologies Corp: 1 director
A director at Sensient Technologies Corp sold 4,518 shares at 94.809USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare C...
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference taking place from December 2 - 4, 2025 in Coral Gables, Florida. Fireside Chat Details:Event: 8th Annual Evercore Healthcare ConferenceDate/Time: Wednesday, December 3rd, 2025 at 3:25 pm ET A ...
NYLI MacKay DefinedTerm Muni Opportunities Fund: 1 director
A director at NYLI MacKay DefinedTerm Muni Opportunities Fund sold 11,965 shares at 14.840USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recen...
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase 1 Multiple Myeloma Data Support Potential Best-in-Class Profile With a 53% Overall Response Rate at the Highest Dose Level (100 µg) and Differentiated Safety and Tolerability Profile Entered Into Clinical Trial Collaboration and Supply Agreement With Pfizer to Evaluate Cemsidomide ...
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offerin...
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering $125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with Elranatamab Potential to Earn up to an Additional $225 Million in Proceeds WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the pricing o...
Quaint Oak Bancorp, Inc. Declares Quarterly Cash Dividend
Quaint Oak Bancorp, Inc. Declares Quarterly Cash Dividend SOUTHAMPTON, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Quaint Oak Bancorp, Inc. (OTCQB: QNTO) (the "Company"), the holding company for Quaint Oak Bank, announced today that its Board of Directors declared a quarterly cash dividend of $0.04 per share on the common stock of the Company on October 8, 2025. The dividend is payable on November 3, 2025, to the shareholders of record at the close of business on October 20, 2025. Quaint Oak Bancorp, Inc., a Financial Services Company, is the parent company for the Quaint Oak Family of Compan...
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agre...
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the agreement, Pfizer will supply elranatamab (ELREXFIO®), a B-cell m...
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Sup...
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma Patient Population Responses Across Dose Levels With Median Duration of Response of 9.3 Months as of the Data Cut-off Date; Median Duration of Response Not Yet Reached at Two Highest Doses No Discontinuations ...
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that its partner Biogen has had its investigational new drug (IND) application for BIIB142 accepted by the U.S. Food and Drug Administration (FDA). BIIB142 is a degrader of IRAK4 that Biogen intends to explore for therapeuti...
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide ...
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting C4T to Host Webcast on September 20, 2025 at 3 pm ET WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (...
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Rece...
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose Level and at 50% at the 100 µg Dose Level Productive Type C Meeting Held With FDA; Registrational Development of Cemsidomide in Multiple Myeloma on Track to Initiate in Early 2026 Preclinical Milestone Achieved Under the Collaboration With Merck KGaA, Darmstadt, Germany, Which ...
QUAINT OAK BANCORP, INC. ANNOUNCES SECOND QUARTER EARNINGS
QUAINT OAK BANCORP, INC. ANNOUNCES SECOND QUARTER EARNINGS Southampton, PA , July 31, 2025 (GLOBE NEWSWIRE) -- Quaint Oak Bancorp, Inc. (the “Company”) (OTCQB: QNTO), the holding company for Quaint Oak Bank (the “Bank”), announced today net income for the quarter ended June 30, 2025 of $272,000, or $0.10 per basic and diluted share, compared to net income of $100,000, or $0.04 per basic and diluted share, for the same period in 2024. Net income for the six months ended June 30, 2025 was $189,000, or $0.07 per basic and diluted share, compared to net income of $973,000, or $0.39 per basic ...
Quaint Oak Bancorp, Inc. Declares Quarterly Cash Dividend
Quaint Oak Bancorp, Inc. Declares Quarterly Cash Dividend SOUTHAMPTON, Pa., July 11, 2025 (GLOBE NEWSWIRE) -- Quaint Oak Bancorp, Inc. (OTCQB: QNTO) (the “Company”), the holding company for Quaint Oak Bank, announced today that its Board of Directors declared a quarterly cash dividend of $0.04 per share on the common stock of the Company on July 9, 2025. The dividend is payable on August 4, 2025, to the shareholders of record at the close of business on July 21, 2025. Robert T. Strong, Chief Executive Officer of the Company stated, “After careful consideration, the Board decided to reduce...
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recen...
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One Patient With a Minimal Residual Disease Negative Complete Response; 40% ORR Achieved at the 75 µg Dose Level Cemsidomide Multiple Myeloma Dose Escalation is Complete; FDA Feedback Expected by Mid-Year 2025 to Support Initiation of Next Phase of Development in Early 2026 ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.